Press Releases Harrow, Inc.

Equities

HROW

US4158581094

Market Closed - OTC Markets Other stock markets 04:00:00 2024-06-06 pm EDT			5-day change	1st Jan Change
17.96 ^USD	+0.22%		+0.67%	+60.36%

Jun. 05	Harrow, Inc. Announces 52-Week Data from VEVYE ESSENCE-2 Open-Label Extension Study	CI
Jun. 03	Lake Street Raises Price Target on Harrow to $25 From $20, Maintains Buy Rating	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Harrow Announces 52-Week Data from VEVYE ESSENCE-2 Open-Label Extension Study	Jun. 06	AQ
Harrow to Present at Two Investor Conferences in May	May. 16	AQ
Harrow : Q1-2024 Letter to Stockholders	May. 13	PU
Harrow Will Release First Quarter 2024 Financial Results After Market Close on May 13, 2024	Apr. 26	AQ
Melt Pharmaceuticals Closes $24 Million Series B Preferred Stock Financing	Apr. 03	AQ
Harrow Announces Fourth Quarter and Year-End 2023 Financial Results	Mar. 20	AQ
Harrow : Q4-2023 Letter to Stockholders	Mar. 19	PU
Harrow Will Release Fourth Quarter and Year-End 2023 Financial Results after Market Close on March 19, 2024	Mar. 06	AQ
Harrow Announces New Appointments to its Board of Directors	Jan. 30	AQ
Harrow Announces Availability of VEVYE 0.1%, the First and Only Cyclosporine-Based Product Indicated for Treating Both Signs and Symptoms of Dry Eye Disease	Jan. 12	AQ
Harrow Partners with Leading Healthcare Market Access Technology Platforms	Jan. 04	AQ
Melt Pharmaceuticals Provides Corporate Update	Jan. 04	AQ
Harrow Completes Transfer of the TRIESENCE New Drug Application	Nov. 30	AQ
Harrow to Present at Two Investor Conferences in November	Nov. 21	AQ
Harrow Will Release Third Quarter 2023 Financial Results on November 13, 2023	23-10-31	AQ
Harrow Completes Transfer of NDAs and Launches FLAREX, NATACYN, TOBRADEX ST, VERKAZIA, and ZERVIATE in the U.S.	23-10-25	AQ
Harrow Health, Inc. Changes Corporate Name to Harrow, Inc.	23-10-02	AQ
Melt Pharmaceuticals Announces Exclusive Development and License Agreement with Catalent for Its Zydis Fast-Dissolve Technology for Use in MELT-300 for Needle- and Opioid-Free Procedural Sedation	23-09-27	AQ
Harrow: Q2 Earnings Snapshot	23-08-09	AQ
Harrow Health : Q2-2023 Letter to Stockholders	23-08-09	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Harrow, Inc.

Equities

HROW

US4158581094

Press Releases

Filters